Rapport Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Rapport Therapeutics, Inc. on June 10, 2026. The record date for the meeting was April 14, 2026, with 47,807,623 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1 (Election of Directors): Stockholders approved the election of three Class II directors to serve until the 2029 annual meeting.
- James Healy, M.D., Ph.D.: 41,762,713 For; 587,163 Withheld; 1,983,035 Broker Non-Votes.
- Robert J. Perez: 37,592,089 For; 4,757,787 Withheld; 1,983,035 Broker Non-Votes.
- Raymond Sanchez, M.D.: 41,754,131 For; 595,745 Withheld; 1,983,035 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes: 44,255,547 For; 57,445 Against; 19,919 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new board composition with three directors elected for a three-year term.
- Verification of the significant number of broker non-votes (1,983,035) on the director election, which may indicate shares held in street name where brokers lacked discretionary voting authority.
- Review of the Definitive Proxy Statement filed on April 23, 2026, for detailed background on the nominees and auditor selection.